Antiviral Effect of Budesonide against SARS-CoV-2
Open Access
- 20 July 2021
- Vol. 13 (7), 1411
- https://doi.org/10.3390/v13071411
Abstract
Treatment options for COVID-19, a disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, are currently severely limited. Therefore, antiviral drugs that efficiently reduce SARS-CoV-2 replication or alleviate COVID-19 symptoms are urgently needed. Inhaled glucocorticoids are currently being discussed in the context of treatment for COVID-19, partly based on a previous study that reported reduced recovery times in cases of mild COVID-19 after inhalative administration of the glucocorticoid budesonide. Given various reports that describe the potential antiviral activity of glucocorticoids against respiratory viruses, we aimed to analyze a potential antiviral activity of budesonide against SARS-CoV-2 and circulating variants of concern (VOC) B.1.1.7 (alpha) and B.1.351 (beta). We demonstrate a dose-dependent inhibition of SARS-CoV-2 that was comparable between all viral variants tested while cell viability remains unaffected. Our results are encouraging as they could indicate a multimodal mode of action of budesonide against SARS-CoV-2 and COVID-19, which could contribute to an improved clinical performance.Keywords
This publication has 27 references indexed in Scilit:
- A Novel Coronavirus from Patients with Pneumonia in China, 2019The New England Journal of Medicine, 2020
- Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory SyndromeAmerican Journal of Respiratory and Critical Care Medicine, 2018
- Antiviral and anti-inflammatory activity of budesonide against human rhinovirus infection mediated via autophagy activationAntiviral Research, 2018
- Effect of nebulized budesonide on respiratory mechanics and oxygenation in acute lung injury/acute respiratory distress syndrome: Randomized controlled studySaudi Journal of Anaesthesia, 2017
- Immediate Antiinflammatory Effects of Inhaled Budesonide in Patients with AsthmaAnnals of the American Thoracic Society, 2014
- Budesonide and Formoterol Reduce Early Innate Anti-Viral Immune Responses In VitroPLOS ONE, 2011
- Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.European Respiratory Journal, 2003
- Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide aloneEuropean Respiratory Journal, 2001
- Acute Anti-inflammatory Effects of Inhaled Budesonide in AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Inhaled Budesonide Decreases Airway Inflammatory Response to AllergenAmerican Journal of Respiratory and Critical Care Medicine, 2000